We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Lipocalin 2 Proposed as Biomarker for Bacterial Meningitis

By LabMedica International staff writers
Posted on 05 Aug 2020
Print article
Image: The Quantikine ELISA Human Lipocalin-2/NGAL Kit is a solid phase sandwich ELISA that quantifies human Lipocalin-2/NGAL in serum, heparin plasma, saliva, and urine (Photo courtesy of R&D Systems).
Image: The Quantikine ELISA Human Lipocalin-2/NGAL Kit is a solid phase sandwich ELISA that quantifies human Lipocalin-2/NGAL in serum, heparin plasma, saliva, and urine (Photo courtesy of R&D Systems).
Central nervous system (CNS) infections cause significant mortality and morbidity worldwide. Common CNS infections include bacterial meningitis (BM) other than tuberculosis, viral encephalitis, tuberculous meningitis (TBM) and cryptococcal meningitis, but there are more than 100 documented infectious causes of CNS infections.

Clinical features are often insufficient to discriminate the likely cause and standard laboratory investigations identify the causative agent in less than 60% of cases. Critically, the clinical management of CNS infections varies according to its etiology. Therefore, rapid and accurate identification of the likely cause of the infection is essential to initiate appropriate therapy and improve patient outcome.

Scientists from the Oxford University Clinical Research Unit (Ho Chi Minh City, Vietnam) and their associates applied liquid chromatography tandem mass-spectrometry on 45 cerebrospinal fluid (CSF) samples from a cohort of adults with/without CNS infections to discover potential diagnostic biomarkers. They then validated the diagnostic performance of a selected biomarker candidate in an independent cohort of 364 consecutively treated adults with CNS infections admitted to a referral hospital in Vietnam.

Measurement of lipocalin 2 (LCN2) concentrations was performed on CSF samples and a subset of plasma samples of the study participants using monoclonal antibody based Quantikine ELISA kits (R&D Systems, Minneapolis, MN, USA) which costs around USD 10/test. CSF was analyzed as individual samples using proteomic platforms. MS/MS spectra were searched against the UniProt Homo Sapiens Reference proteome. Deamidation on asparagine and glutamine and oxidation on methionine were included as variable modifications.

The team identified LCN2 as a potential biomarker of BM other than tuberculous meningitis. The analysis of the validation cohort showed that LCN2 could discriminate BM from other CNS infections (including tuberculous meningitis, cryptococcal meningitis and viral/antibody-mediated encephalitis), with the sensitivity of 0.88, the specificity equaled 0.91 and the diagnostic odds ratio was 73.8. LCN2 outperformed other CSF markers (leukocytes, glucose, protein and lactate) commonly used in routine care worldwide. The combination of LCN2, CSF leukocytes, glucose, protein and lactate resulted in the highest diagnostic performance for BM (area under receiver-operating-characteristic-curve = 0.96).

The authors concluded that their results suggest that LCN2 is a sensitive and specific biomarker for discriminating BM from a broad spectrum of other CNS infections. A prospective study is needed to assess the diagnostic utility of LCN2 in the diagnosis and management of CNS infections. The study was published on July 10, 2020 in the journal Clinical Microbiology and Infection.

Related Links:
Oxford University Clinical Research Unit
R&D Systems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.